Literature DB >> 1721344

Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report.

L A Mieles1, J J Fung, I Yokoyama, J McCauley, N Singh, S Todo, R D Gordon, T E Starzl.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1721344      PMCID： PMC2974314     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

1.  Initial two-year results of the Oregon Liver Transplantation Program.

Authors:  C W Pinson; R R Lopez; K G Benner; E B Keeffe; M K Porayko; A W Sasaki; D K Bowers; L J Wheeler; R G Lee; R S Johnson
Journal:  Am J Surg       Date:  1991-05       Impact factor: 2.565

2.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Early trials with FK 506 as primary treatment in liver transplantation.

Authors:  S Todo; J J Fung; A J Demetris; A Jain; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Infections in adult liver transplant patients under FK 506 immunosuppression.

Authors:  M Alessiani; S Kusne; M Martin; A Jain; K Abu-Elmagd; J Moser; S Todo; J Fung; T Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

Authors:  L Mieles; R D Gordon; D Mintz; R M Toussaint; O Imventarza; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

6.  Liver transplantation. Initial experience in the Veterans Administration.

Authors:  R I Leventhal; D H Berman; S Lasky; J S Gavaler; V Dindzans; E Urban; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

7.  The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.

Authors:  J P Boudreaux; L McHugh; D M Canafax; N Ascher; D E Sutherland; W Payne; R L Simmons; J S Najarian; D S Fryd
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

8.  Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients.

Authors:  N Yoshimura; I Nakai; Y Ohmori; I Aikawa; M Fukuda; T Yasumura; S Matsui; T Hamashima; T Oka
Journal:  Am J Kidney Dis       Date:  1988-07       Impact factor: 8.860

9.  Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.

Authors:  N Singh; J S Dummer; S Kusne; M K Breinig; J A Armstrong; L Makowka; T E Starzl; M Ho
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients.

Authors:  D Roth; M Milgrom; V Esquenazi; L Fuller; G Burke; J Miller
Journal:  Transplantation       Date:  1989-02       Impact factor: 4.939
  10 in total
  4 in total

1.  Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506?

Authors:  N Singh; L Mieles; V L Yu; T E Starzl
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

2.  Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity.

Authors:  T Gayowski; I R Marino; N Singh; H Doyle; M Wagener; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1998-02-27       Impact factor: 4.939

3.  A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation.

Authors:  T J Gayowski; I R Marino; H R Doyle; L Echeverri; L Mieles; S Todo; M Wagener; N Singh; V L Yu; J J Fung; T E Starzl
Journal:  J Surg Res       Date:  1996-02-01       Impact factor: 2.192

4.  Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial.

Authors:  D H Van Thiel; H Wright; P Carroll; K Abu-Elmagd; H Rodriguez-Rilo; J McMichael; W Irish; T E Starzl
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.